OGC
ALXN

One68 Global Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

One68 Global Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.57M Buy
+10,049
New +$1.29M 3.15% 6

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

One68 Global Capital's ALXN Position: Q4 2020 in Review

One68 Global Capital opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2020: 10,049 shares worth $1.57M. The stake represents 3.15% of the portfolio and ranks #6 among its holdings.

825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • One68 Global Capital held 10,049 shares of Alexion Pharmaceuticals worth $1.57M as of Q4 2020.
  • Alexion Pharmaceuticals was a new One68 Global Capital position in Q4 2020.
  • Alexion Pharmaceuticals made up 3.15% of One68 Global Capital's portfolio in Q4 2020, its #6 holding.
  • 825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on One68 Global Capital's 13F filing for Q4 2020, filed 16 Feb 2021.